Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -1.3% 38.00 265,260 08:00:12
Bid Price Offer Price High Price Low Price Open Price
37.00 39.00 38.00 38.00 38.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -9.58 -8.10 48
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:11 O 150,000 38.00 GBX

C4x Discovery (C4XD) Latest News

More C4x Discovery News
C4x Discovery Investors    C4x Discovery Takeover Rumours

C4x Discovery (C4XD) Discussions and Chat

C4x Discovery Forums and Chat

Date Time Title Posts
02/3/202120:39C4X Discovery Holdings plc2,422

Add a New Thread

C4x Discovery (C4XD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all C4x Discovery trades in real-time

C4x Discovery (C4XD) Top Chat Posts

C4x Discovery Daily Update: C4x Discovery Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker C4XD. The last closing price for C4x Discovery was 38.50p.
C4x Discovery Holdings Plc has a 4 week average price of 30.50p and a 12 week average price of 20.60p.
The 1 year high share price is 39.50p while the 1 year low share price is currently 8p.
There are currently 127,176,716 shares in issue and the average daily traded volume is 3,501,134 shares. The market capitalisation of C4x Discovery Holdings Plc is £48,327,152.08.
alloa2003: We can assume next INDV payment is in the bag. They have already said the next two which are furthest down the line are even bigger. Have they also found other molecules they can develop and commercialise? Any weakness in the share price - even the multi million share stakes changing hands - has promped buyers to come back in. I would love to know what is going on behind the scenes. The horror low of 7p is hopefully behind us forever!
alloa2003: Still no news - its been months now since we had any news on deals. There must be something going on behind the scenes otherwise the share price would have fallen back. When will we see some developments?
wadget: Nice mention of C4XD on BBC news.. hTTps:// Could C4XD be providing technology "allowing scientists to "second-guess" mutations that have not yet occurred" All getting very exciting..
alloa2003: The share price has been very very strong lately, even when the sellers emerged. I agree, I dont think an announcement can be too far away. However, I also have a sneaking suspicion that there may be other stuff going on as well - new deal(s)?
alloa2003: While I agree to a certain extent - the whole concept of options is to incentise people. Fixing the option price at current levels is not what they were meant for. Lets not forget the directors were still receiving their salaries while the shares were falling. They havent suffered as yet. You say it isnt much of a reward for a 5 fold increase in the share price. Well it was £1 a share just over 2 years ago. So I hardly think a return to those levels justifies a "reward for success". Especially when you realise they have burnt the INDV down payment and a chunk of other fund raisings, with nothing additional to show for the money, as yet. If the directors deliver as they say they can, then these shares will be well north of a pound in the short to medium term. Time to deliver.
1aconic: Yeah, they're cheap but they haven't been given huge volume. The other options they all have all seem to be around 90p and above. From here, developments that drive the price above £1 would make them worth 160k each on these options. That's not really an excessive bonus relative to a five fold share price increase (albeit from the current levels rather than those of 2018).
alloa2003: Are the directors taking us for fools? Where is the incentive to push the share price? The exercise price should have been 50p minimum. If all is good behind the scenes, as they keep telling us, then 50p should not be a problem. As a % of the share capital it is irrelevant but it is the principle of institutions and now directors taking advantage of the relatively depressed share price (compared to 12 months ago).
alloa2003: Emailed C4XD today. Lets see if I get a reply:- I am an investor in C4XD and have been since the heady days when the shares were 50p+. During the last 12 months we have seen numerous fund raisings which have diluted private investors with the constant promise these funds will result in a stronger business. So far we have had next to no updates on existing treatments let alone any new ones, we have heard endless promises that partnership deals are in the offing but absolutely nothing to report. As a concept I believe strongly in this company but your PR skills are atrocious and the only winners lately have been the institutions taking on cheap stock at our expense. When can we expect any meaningful updates? When can we expect to see progress? I notice that Mr Dix is involved in a government Covid research project. At the moment it looks as though this is to the severe detriment of the company. If that is the case, you need to find a replacement asap to push the company along. A company that has raised a relatively huge amount of money lately which is disappearing each month with, so far, absolutely nothing to show for it. Unless results are forthcoming, I very much doubt the market will accept another fund raising even at the hugely dilutive levels which seem to have become the norm with C4XD.
the stigologist: Perfectly normal for Deputy Chair of UK Vaccine Taskforce to speak to Bill Gates Interestingly Bill Gates is one of biggest investors in Schrodinger (SDGR) Mkt Cap $5bn Schrodinger is the nearest equivalent to C4XD IF C4XD share price doesn't go up soon I can see a US Company snapping them up for 100p+ The Indivior deal alone at $294m makes C4XD cheap at 100p (c.£130m Mkt Cap) Clive today told us the NRF2/IL17/a4B7 projects have similar potential
alloa2003: Nice update with a mention of work in the area of Covid-19:- 25 August 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today provides a business update. Clive Dix, CEO of C4XD, commented: "I am delighted to share the progress we have made over recent months across our proprietary portfolio despite the challenges of the COVID-19 pandemic, in particular, the continued headway in our key inflammation programmes. Importantly, Indivior recently commenced a Phase 1 clinical trial with our selective Orexin-1 antagonist, C4X_3256, for the treatment of opioid dependence and we eagerly await those results in due course. Our two most advanced programmes, NRF-2 and IL-17, continue to move forward with one of our lead NRF-2 molecules, C4X_6746, showing significant efficacy in a pre-clinical model of Inflammatory Bowel Disease (IBD). This enables expansion of our commercial discussions beyond those partners already engaged in assessing the programme for Pulmonary Arterial Hypertension and Sickle Cell Disease. "We are also pleased to announce a new partnership with the GEN-COVID Consortium in Italy. The collaboration will utilise Taxonomy3® to examine genetic data from a significant number of COVID-19 patients to identify genes specifically associated with severe COVID-19 disease. The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis. This is a new area for C4XD and we are excited to be working on such an important project. We remain committed to deliver and drive novel small molecule drugs against challenging targets towards clinical development." C4XD has continued to make progress across key programmes in its portfolio: · Indivior has commenced a Phase 1 clinical trial for C4XD's novel selective Orexin-1 antagonist, C4X_3256 (also known as INDV-2000), for the treatment of opioid dependence with the first patient now dosed (hxxps:// This single ascending dose study in healthy volunteers is anticipated to complete by year end. · One of C4XD's lead NRF-2 activator molecules C4X_6746, has recently been shown to significantly inhibit the disease score in a pre-clinical model of IBD in a dose-related manner. Candidate nomination studies continue. · The lead optimisation stage has been initiated for C4XD's novel oral IL-17 inhibitor programme for the treatment of Psoriasis with the aim of identifying further improved small molecules to drive towards a pre-clinical candidate shortlist. We note that Leo Pharma A/S has recently announced that it has identified the first oral IL-17 inhibitor IND-ready candidate with clinical studies expected to be initiated soon. This provides further confidence that the challenge of developing a small molecule alternative to injectable monoclonal antibodies to target IL-17 can be achieved and there has been increased interest from potential pharma partners. · Significant progress has been made on C4XD's early oral inhibitor programme targeting a4b7 integrin for the treatment of IBD. Effective antibody therapy against this target is already approved, removing the clinical target risk, but effective oral therapy remains highly sought after. C4XD has identified a second series of novel, potent and selective inhibitors providing a further competitive edge for this programme. This reaffirms the capability of C4XD's Conformetrix technology to discover novel chemical scaffolds for high-value challenging drug targets. Both series have recently demonstrated oral bioavailability in PK studies with the current focus on improving PK properties to demonstrate functional inhibition of a4b7 integrin in vivo following oral dosing. · The LifeArc risk-share collaboration on an oral small molecule inhibitor programme for the treatment of haematological cancers and inflammatory disease continues to progress well despite being impacted by COVID-19. Three novel series have been identified by harnessing C4XD's Conformetrix technology and recent data has demonstrated functional cell activity and oral bioavailability for all three series. Optimisation continues with the aim of demonstrating functional inhibition of the target in vivo following oral dosing. · C4XD has recently entered a new collaboration with the GEN-COVID consortium, a network of more than 20 hospitals in Italy led by Professor Alessandra Renieri of the University of Siena. The collaboration will use the unique mathematical genetic analysis methodology of Taxonomy3® to investigate the role genetics plays in the widely varied disease susceptibility, severity and prognosis observed between individuals with COVID-19. Taxonomy3® will analyse genetic data from a significant number of COVID-19 positive patients collected by the consortium to identify genes associated with severe COVID-19 disease. The aim is to identify a unique genetic signature that can successfully predict mild vs. severe disease to inform treatment of patients at risk. The analysis may also uncover novel biology driving severity of the disease which may inform potential novel drug targets for treatment.
C4x Discovery share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210305 23:54:56